OTCMKTS:ELTP - Elite Pharmaceuticals, Inc. Common Stock Stock Price, News, Headlines & Rumors

Sign in or create an account to add this stock to your watchlist.
$0.1033 -0.01 (-6.09 %)
(As of 08/14/2018 04:21 AM ET)
Previous Close$0.11
Today's Range$0.1010 - $0.1110
52-Week Range$0.0560 - $0.1450
Volume1.24 million shs
Average Volume814,303 shs
Market Capitalization$88.80 million
P/E RatioN/A
Dividend YieldN/A
Beta0.52
Elite Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the research, development, manufacture, and licensing of proprietary orally administered controlled-release drug delivery systems and products. The company operates in Abbreviated New Drug Applications for Generic Products and New Drug Applications for Branded Products segments. It owns, licenses, and contract manufactures various generic and oral dose pharmaceuticals products, such as Phentermine HCl 15mg and 30mg capsules, and 37.5mg tablets for the treatment of bariatrics under Adipex-P brand name; Lodrane D immediate release capsules for OTC allergy treatment; Methadone HCl 10mg tablets for pains under the Dolophine name; and Hydromorphone HCl 8mg tablets for pains under the Dilaudid name. The company also provides Phendimetrazine Tartrate 35mg tablets for bariatrics under the Bontril name; Naltrexone HCl 50mg tablets for the treatment of pains under the Revia name; Isradipine 2.5mg and 5mg capsules for cardiovascular diseases; Hydroxyzine HCl 10mg, 25mg, and 50mg tablets for antihistamine treatment under Atarax and Vistaril brand names; Oxycodone HCl immediate release 5mg, 10mg, 15mg, 20mg, and 30mg tablets for pains under Roxycodone name; and Trimipramine Maleate Immediate Release 25mg, 50mg, and 100mg antidepressant capsules under the Surmontil brand, as well as SequestOX, an immediate release Oxycodone with Naltrexone. In addition, it manufactures controlled-release products on a contract basis for third parties in the areas of pain, allergy, bariatric, and infection. Further, the company is developing a range of abuse deterrent opioid products. It has a manufacturing and license agreement with Epic Pharma LLC; manufacturing and supply agreement with The PharmaNetwork LLC; development and license agreement with SunGen Pharma, LLC; and strategic marketing alliance with Glenmark Pharmaceuticals, Inc. USA. The company was founded in 1984 and is headquartered in Northvale, New Jersey.

Receive ELTP News and Ratings via Email

Sign-up to receive the latest news and ratings for ELTP and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange OTCMKTS
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolOTCMKTS:ELTP
CUSIPN/A
Phone201-750-2646

Debt

Debt-to-Equity Ratio0.73
Current Ratio2.68
Quick Ratio1.72

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$7.46 million
Price / Sales11.18
Cash FlowN/A
Price / CashN/A
Book Value$0.01 per share
Price / Book10.33

Profitability

EPS (Most Recent Fiscal Year)N/A
Net Income$-3,670,000.00
Net Margins-40.28%
Return on Equity-57.17%
Return on Assets-10.08%

Miscellaneous

Employees43
Outstanding Shares807,230,000
Market Cap$88.80 million

Elite Pharmaceuticals, Inc. Common Stock (OTCMKTS:ELTP) Frequently Asked Questions

What is Elite Pharmaceuticals, Inc. Common Stock's stock symbol?

Elite Pharmaceuticals, Inc. Common Stock trades on the OTCMKTS under the ticker symbol "ELTP."

How were Elite Pharmaceuticals, Inc. Common Stock's earnings last quarter?

Elite Pharmaceuticals, Inc. Common Stock (OTCMKTS:ELTP) issued its quarterly earnings results on Thursday, June, 14th. The specialty pharmaceutical company reported $0.00 EPS for the quarter. The specialty pharmaceutical company earned $1.60 million during the quarter. Elite Pharmaceuticals, Inc. Common Stock had a negative net margin of 40.28% and a negative return on equity of 57.17%. View Elite Pharmaceuticals, Inc. Common Stock's Earnings History.

When is Elite Pharmaceuticals, Inc. Common Stock's next earnings date?

Elite Pharmaceuticals, Inc. Common Stock is scheduled to release their next quarterly earnings announcement on Thursday, November, 8th 2018. View Earnings Estimates for Elite Pharmaceuticals, Inc. Common Stock.

Who are some of Elite Pharmaceuticals, Inc. Common Stock's key competitors?

Who are Elite Pharmaceuticals, Inc. Common Stock's key executives?

Elite Pharmaceuticals, Inc. Common Stock's management team includes the folowing people:
  • Mr. Nasrat Hakim, Chairman, CEO & Pres (Age 57)
  • Mr. Carter J. Ward, CFO, Chief Accounting Officer, Treasurer & Sec. (Age 54)
  • Mr. Douglas Plassche, Exec. VP of Operations (Age 54)
  • Dr. George Kenneth Smith J.D., M.B.A., Ph.D., VP of Legal
  • Ms. Dianne Will, VP of Investor Relations & Corp. Affairs

Has Elite Pharmaceuticals, Inc. Common Stock been receiving favorable news coverage?

Media stories about ELTP stock have trended somewhat positive recently, according to Accern Sentiment Analysis. The research group identifies negative and positive media coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Elite Pharmaceuticals, Inc. Common Stock earned a news impact score of 0.10 on Accern's scale. They also gave news headlines about the specialty pharmaceutical company an impact score of 47.07 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future. View Recent Headlines for Elite Pharmaceuticals, Inc. Common Stock.

How do I buy shares of Elite Pharmaceuticals, Inc. Common Stock?

Shares of ELTP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Elite Pharmaceuticals, Inc. Common Stock's stock price today?

One share of ELTP stock can currently be purchased for approximately $0.1033.

How big of a company is Elite Pharmaceuticals, Inc. Common Stock?

Elite Pharmaceuticals, Inc. Common Stock has a market capitalization of $88.80 million and generates $7.46 million in revenue each year. Elite Pharmaceuticals, Inc. Common Stock employs 43 workers across the globe.

How can I contact Elite Pharmaceuticals, Inc. Common Stock?

Elite Pharmaceuticals, Inc. Common Stock's mailing address is 165 LUDLOW AVENUE, NORTHVALE NJ, 07647. The specialty pharmaceutical company can be reached via phone at 201-750-2646 or via email at [email protected]


MarketBeat Community Rating for Elite Pharmaceuticals, Inc. Common Stock (OTCMKTS ELTP)

Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  47 (Vote Outperform)
Underperform Votes:  58 (Vote Underperform)
Total Votes:  105
MarketBeat's community ratings are surveys of what our community members think about Elite Pharmaceuticals, Inc. Common Stock and other stocks. Vote "Outperform" if you believe ELTP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ELTP will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 8/14/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.